Neil S. Belloff's most recent trade in Acorda Therapeutics Inc was a trade of 77,300 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 31, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Inc | Neil S. Belloff | General Counsel and Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 77,300 | 77,300 | - | - | Employee Stock Option (right to buy) | |
| Acorda Therapeutics Inc | Neil S. Belloff | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2021 | 85,000 | 85,000 | - | - | Employee Stock Option (right to buy) | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 6,250 | 68,750 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 6,250 | 33,430 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 25 May 2021 | 1,835 | 31,595 (0%) | 0% | 1.4 | 2,551 | Common Stock |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 1,562 | 27,639 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 1,562 | 10,938 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.18 per share. | 30 Apr 2021 | 459 | 27,180 (0%) | 0% | 2.2 | 1,001 | Common Stock |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 25,000 | 75,000 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 25,000 | 33,415 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.95 per share. | 25 Feb 2021 | 7,338 | 26,077 (0%) | 0% | 3.9 | 28,985 | Common Stock |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 120,000 | 120,000 | - | - | Stock Options | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2021 | 1,563 | 8,957 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2021 | 1,563 | 12,500 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.44 per share. | 30 Jan 2021 | 542 | 8,415 (0%) | 0% | 3.4 | 1,864 | Common Stock |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 1,562 | 7,853 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 1,562 | 14,063 | - | - | Restricted Stock Units | |
| Eloxx Pharmaceuticals Inc | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.53 per share. | 30 Oct 2020 | 459 | 7,394 (0%) | 0% | 2.5 | 1,161 | Common Stock |